QIAGEN (QGEN) Stock: Buy, Sell, or Hold?
QGEN - QIAGEN N.V.
$42.50
0.37 (0.88%)
â˛
5d:
-3.1%
30d:
-1.16%
90d:
+13.58%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When QGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: QGEN is fairly priced but lacks strong directional signals. At 0.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: QGEN is fairly priced but lacks strong directional signals. At 0.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$54.82
Based on 5.6% avg growth
INTRINSIC VALUE TODAY
$34.04
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: QGEN is currently trading at $42.50, which is considered slightly low relative to its 30-day fair value range of $42.27 to $43.91. The stock's valuation (Forward PE: 16.3) is in line with its historical norms (16.0). At these levels, the market is pricing in 0.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, QGEN is in a strong uptrend. The price is currently testing key support at $41.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: QGEN scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, QGEN is in a strong uptrend. The price is currently testing key support at $41.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: QGEN scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$42.27 -
$43.91
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
53.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (34/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($46.07)
- NEUTRAL: Market pricing in 0.7% annual earnings growth - fairly valued
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$42.27 -
$43.91
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$41.89
Resistance Level
$44.92
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.29
Wall Street Target
$46.07
(+8.4%)
Revenue Growth (YoY)
0.3%
Earnings Growth (YoY)
7.9%
Profit Margin
19.5%
Valuation Premium vs History
+0.7% premium
PE vs Historical
16.3 vs 16.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.7%
(market-implied from PE analysis)
1-Year Target
$42.80
(+1%)
2-Year Target
$43.10
(+1%)
3-Year Target
$43.40
(+2%)
3-Yr Target (if PE normalizes)
(PE: 16â16)
PE COMPRESSION
$42.64
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 7.2%)
$64.90
(+53%)
Base:
(SPY PE: 16.3, Growth: 7.2%)
$52.40
(+23%)
Bear:
(PE: 13.8, Growth: 7.2%)
$44.54
(+5%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 21.61 | Current EPS (TTM): $1.95
Bull Case
$62.02
(+46%)
Analyst growth 33.8%, PE expands to 23.8
Base Case
$56.38
(+33%)
Market implied 33.8%, PE stable at 21.6
Bear Case
$28.65
(-33%)
Severe decline -20.0%, PE contracts to 18.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 1:33 AM ET
Data refreshes hourly during market hours. Next update: 2:33 AM
Data refreshes hourly during market hours. Next update: 2:33 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
31 analysts |
$638 | 51 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$229 | 49 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$194 | 49 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$338 | 47 HOLD |
